CA2175081A1 - Vaccin et procede de traitement contre les infections a chlamydia - Google Patents

Vaccin et procede de traitement contre les infections a chlamydia

Info

Publication number
CA2175081A1
CA2175081A1 CA 2175081 CA2175081A CA2175081A1 CA 2175081 A1 CA2175081 A1 CA 2175081A1 CA 2175081 CA2175081 CA 2175081 CA 2175081 A CA2175081 A CA 2175081A CA 2175081 A1 CA2175081 A1 CA 2175081A1
Authority
CA
Canada
Prior art keywords
momp
vaccine
preparation
chlamydia
lps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2175081
Other languages
English (en)
Inventor
James Evan Sandbulte
Marta Iris Sabara
Julie Ann Terwee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2175081A1 publication Critical patent/CA2175081A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vaccin destiné au traitement des infections à chlamydia, constitué d'une préparation de protéine de membrane externe majeure (MOMP) et d'une préparation de lipopolysaccharide (LPS) obtenue à partir d'un organisme porteur de chlamydia. Procédé de traitement et d'immunisation des animaux contre les infections à chlamydia.
CA 2175081 1993-11-03 1994-11-02 Vaccin et procede de traitement contre les infections a chlamydia Abandoned CA2175081A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14763693A 1993-11-03 1993-11-03
US08/147,636 1993-11-03

Publications (1)

Publication Number Publication Date
CA2175081A1 true CA2175081A1 (fr) 1995-05-11

Family

ID=22522314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2175081 Abandoned CA2175081A1 (fr) 1993-11-03 1994-11-02 Vaccin et procede de traitement contre les infections a chlamydia

Country Status (7)

Country Link
EP (1) EP0726775A4 (fr)
CN (1) CN1134112A (fr)
AU (1) AU701247B2 (fr)
BR (1) BR9407986A (fr)
CA (1) CA2175081A1 (fr)
NZ (1) NZ276874A (fr)
WO (1) WO1995012411A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184132C (fr) * 1995-09-21 2011-03-15 Kristina J. Hennessy Vaccin avec adjuvant, pratiquement exempt d'albumine non-hote
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
WO2000006743A2 (fr) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Antigenes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
AU2138601A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE463575T1 (de) * 1999-12-22 2010-04-15 Aventis Pasteur Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
WO2001046225A2 (fr) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations
NZ533428A (en) 2001-12-12 2008-03-28 Chiron Srl Immunisation against chlamydia trachomatis
CN103068837B (zh) 2010-05-28 2015-06-24 斯匹遐生物技术公司 嵌合momp抗原、方法和使用
AU2016219379B2 (en) 2015-02-10 2020-11-26 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
CN108367058A (zh) * 2015-11-10 2018-08-03 俄亥俄州创新基金会 与加快的体液亲和力相关的方法和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271146A (en) * 1979-09-06 1981-06-02 Seawell Albert C Methods of using Chlamydia vaccine for preventing and treating bovine and ovine diseases

Also Published As

Publication number Publication date
WO1995012411A1 (fr) 1995-05-11
EP0726775A4 (fr) 1999-03-31
EP0726775A1 (fr) 1996-08-21
AU701247B2 (en) 1999-01-21
BR9407986A (pt) 1996-12-03
CN1134112A (zh) 1996-10-23
NZ276874A (en) 1997-11-24
AU1129795A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
Goto et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties
JP2022078317A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓに対して免疫化するための組成物
ES2374278T3 (es) Vacuna canina para la protección contra la erliquiosis.
KR101099883B1 (ko) 백신 투여 방법
Munir et al. Outer membrane proteins of Brucella abortus vaccinal and field strains and their immune response in buffaloes
McLean et al. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine
Abraham et al. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection
CA2175081A1 (fr) Vaccin et procede de traitement contre les infections a chlamydia
Wang et al. Research progress in live attenuated Brucella vaccine development
Prescott et al. Use of a virulence‐associated protein based enzyme‐linked immunosorbent assay for Rhodococcus equi serology in horses
Zhu et al. Comparison of immune effects between Brucella recombinant Omp10-Omp28-L7/L12 proteins expressed in eukaryotic and prokaryotic systems
CN106103469A (zh) 突变型葡萄球菌抗原
AU769375B2 (en) Vaccine formulation
DE60218662T2 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
KR20010075049A (ko) 성인성질환에 대한 백신
Miao et al. Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines
Parmley et al. Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts
Erturk et al. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection
Sandbulte et al. Evaluation of Chlamydia psittaci subfraction and subunit preparations for their protective capacities
Luke et al. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi
Muñoz et al. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams
Stewart et al. Cross‐protection from Bacteroides nodosus vaccines and the interaction of pili and adjuvants
CA3083977A1 (fr) Vaccin pour la protection contre le streptococcus suis
Moran et al. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead